ABBVAbbVieSigning up patients
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Colorectal Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 990 (planned)
- Started
- May 22, 2026
- Main results expected
- May 2029
- Fully finished
- Mar 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 3: Objective Response (OR) as assessed by Blinded Independent Central Review (BICR)
Measured over: Up to Approximately 15 Months
Phase 3: Overall Survival (OS)
Measured over: Up to Approximately 36 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07525206 · record last updated 2026-10-19 · checked 2026-11-09 15:47 UTC